Pharma News

Crack GPAT — Prepare for GPAT Online 

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Nicox and Kowa inks up for USD 210.65 million for Glaucoma Treatment NCX 470 in U.S.
    17 July 2025

    Nicox and Kowa inks up for USD 210.65 million for Glaucoma Treatment NCX 470 in U.S.

    Nicox SA, an international ophthalmology company, today announced the signing of a major new agreement concerning NCX 470 with Kowa Company, Ltd., a Japanese company with a global pharmaceutical business engaged in ground-breaking research, development and marketing.
  • 17 July 2025
    One drug offers hope for stroke patients

    Stroke is said to be the second leading cause of death worldwide after heart disease. To prevent the death of neurons in the brain, a research group led by Osaka Metropolitan University Associate Professor Hidemitsu Nakajima of the Graduate School of Veterinary Science has developed a drug that inhibits a protein involved in cell death.

  • 16 July 2025
    Breakthrough in Antibiotic Production : Scientists Unlock Genes to Mass-Produce Monensin
    In a significant step forward for industrial biotechnology, researchers have successfully engineered a bacterial strain capable of producing record-breaking levels of monensin, a widely used antibiotic in veterinary medicine and agriculture.
  • 16 July 2025
    FDA approves first interchangeable biosimilar insulin product to Novolog

    Today, the Food and Drug Administration approved, the first rapid-acting interchangeable biosimilar product, Kirsty (insulin aspart-xjhz), as a 3 mL single-patient-use prefilled pen and 10 mL multiple-dose vial. Kirsty is biosimilar to and interchangeable with Novolog (insulin aspart).

    Kirsty is a rapid-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.

  • 16 July 2025
    Sun Pharma launches LEQSELVI™ in the U.S. after patent settlement with Incyte
    Sun Pharmaceutical Industries Limited announced the official launch of LEQSELVI (deuruxolitinib tablets 8 mg) in the United States for the treatment of adults with severe alopecia areata
  • 16 July 2025
    Mouse study finds tirzepatide slowed obesity-associated breast cancer growth
    The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced obesity-associated breast cancer growth in a mouse model, according to a study being presented Saturday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif.
  • 12 July 2025
    Wockhardt to exit U.S. operations to prioritize innovation
    Indian pharmaceutical company Wockhardt has announced a significant strategic shift in its U.S. operations, marking a new chapter focused on innovation-led growth and portfolio rationalization. The company is phasing out its conventional U.S. generics business to channel efforts into high-value specialty products and innovative therapies.
  • 11 July 2025
    Glenmark and AbbVie sign USD 700 million drug licensing agreement
    AbbVie and IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), today announced an exclusive licensing agreement for IGIs lead investigational asset, ISB 2001, developed using IGIs proprietary BEAT protein platform, for oncology and autoimmune diseases
  • 11 July 2025
    Ascentage Pharma Announces Its Novel Bcl-2 Inhibitor Lisaftoclax Approved by China NMPA, Ushering in a New Era for the Treatment of CLL/SLL

    Ascentage Pharma a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that its proprietary novel Bcl-2 selective inhibitor lisaftoclax (APG-2575) has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors, which makes lisaftoclax the first Bcl-2 inhibitor receiving conditional approval

  • 11 July 2025
    Milestone Pharmaceuticals announces FDA acceptance of the Company’s Response to the CRL for CARDAMYST (etripamil) Nasal Spray

    Milestone Pharmaceuticals Inc announced that the U.S. Food and Drug Administration (FDA) has accepted for review Milestone’s response to issues raised in the Complete Response Letter (CRL) for CARDAMYST™ (etripamil) nasal spray, an investigational, novel therapy for the treatment of patients with paroxysmal supraventricular tachycardia (PSVT). The FDA has assigned a new Prescription Drug User Fee Act (PDUFA) target action date of December 13, 2025.

Subscribe to Pharma News